NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
October 16, 2023 07:00 ET
|
NuCana plc
Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy ...
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
October 13, 2023 12:30 ET
|
NuCana plc
NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients Several Second-line...
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
September 18, 2023 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and...
NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
August 16, 2023 16:01 ET
|
NuCana plc
On Track to Present Data Updates from All Ongoing Clinical Studies in the Second Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Aug. 16,...
NuCana to Present at the Jefferies Healthcare Conference
June 01, 2023 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, June 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Reports First Quarter 2023 Financial Results and Provides Business Update
May 17, 2023 16:01 ET
|
NuCana plc
Multiple Important Data Readouts Remain on Track for 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:...
NuCana Announces Receipt of Nasdaq Notice
May 12, 2023 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC...
NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
April 14, 2023 08:00 ET
|
NuCana plc
NUC-7738 Reduces Secreted Forms of PD-L1 Indicating Potential Synergy with Checkpoint Inhibitors NUC-7738 Decreases Glutaminase in vitro and in Cancer Tissue Demonstrating Potential for Anti-Cancer...
NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
April 04, 2023 16:01 ET
|
NuCana plc
Multiple Important Data Readouts Expected in 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, April 04, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA)...
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid
March 24, 2023 16:30 ET
|
NuCana plc
MUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the Technical Board of Appeal (the “TBA”) of the European Patent...